Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection

Lilly’s study finds tirzepatide delivers broader health improvements

Teva’s CGRP therapy becomes first approved option for children and adolescent

Promising results support global submissions and priority review by US FDA

Pirtobrutinib meets primary endpoint in CLL/SLL study

Nationwide competition to pilot new models of obesity support

New phase of development targets chronic pain and fibromyalgia

New treatment option now available across all UK nations

New first-line option for patients with pMMR and dMMR tumours in England

Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US